CagriSema REDEFINE 9: Results and Research Limits
Published · Page updated
Bookmark this page
Save this article in your browser so you can find it again:
- Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
- iPhone or iPad: In Safari, tap Share, then Add Bookmark.
- Android: In Chrome, open the menu and tap the star.
Other browsers may use a different menu.
CagriSema REDEFINE 9 found greater weight reduction with cagrilintide plus semaglutide than with placebo. The November 14, 2026 publication adds evidence about two studied dose levels. It does not prove that a lower dose outperforms a higher dose or establish a personal dosing strategy. Original trial.
Publisher disclosure: Bio Research LLC operates Bio Peptides Labs and sells research materials. This is commercially interested, AI-assisted editorial content, not an independent scientific review. The original indexed abstract and official trial/sponsor materials were checked November 16, 2026. Full journal text and supplements were not independently reviewed. Trial findings do not establish clinical equivalence, safety or efficacy of catalog materials.

What is CagriSema?
CagriSema combines the amylin analogue cagrilintide with the GLP-1 receptor agonist semaglutide. Novo Nordisk funded REDEFINE 9. Original publication.
A combination name identifies components; it does not mean separately obtained materials have the formulation, controls or clinical evidence of the development program.
The broader REDEFINE program includes studies with different populations and comparators. For example, the earlier REDEFINE 1 trial also included individual-component groups. Those results provide context but should not be silently substituted for REDEFINE 9. Original REDEFINE 1 publication.
Who participated in REDEFINE 9?
This 68-week phase 3b trial randomized 309 adults without diabetes who had obesity, or overweight with an obesity-related complication. It compared two combination groups with placebo, alongside nutrition and activity counseling. Blinding was maintained within dose levels. Most participants were women. Original study methods.
The prospective record gives the eligibility and planned outcomes. These details matter when deciding whether a result answers a particular research question: a trial excluding diabetes cannot by itself establish the same effect in people with diabetes. REDEFINE 9 registry. When checked November 19, 2026, the registry listed actual enrollment of 300, whereas the journal abstract reported 309 randomized participants. We use the publication’s randomized count for its results and cannot resolve the discrepancy from these records alone.
What did the weight results show?
For the efficacy analysis, estimated mean weight changes were −20.7% and −21.0% in the two combination groups, versus −2.0% with placebo. Both comparisons with placebo were statistically significant. Adverse events were mostly mild or moderate and gastrointestinal-related; 82% of randomized participants remained on treatment at week 68. Original results.
A different analysis answers a different question:
Analysis | What it estimates | Reported average weight reductions |
|---|---|---|
Efficacy estimand | A scenario in which participants adhere to treatment | 20.7% and 21.0%; placebo 2.0% |
Treatment-regimen estimand | Effect regardless of discontinuation or weight-management rescue intervention | 19.4% and 18.6%; placebo 4.6% |
Paired results are ordered as the 1.7-mg-each trial arm, then the 1.0-mg-each arm; these identify study groups, not personal dosing instructions. Neither row predicts an individual's outcome. Official results and definitions.
Does this mean a lower dose works better?
No. The trial was not powered to compare the two active doses. Numerical differences therefore cannot establish superiority. Trial reporting.
This distinction is useful well beyond CagriSema. Before accepting a “better” claim, ask which comparison was planned, whether uncertainty was reported, and whether the study could reliably answer that comparison. Our study-reading guide explains the difference between a result and a broader inference.
How should readers interpret tolerability?
Adverse-event discontinuations were reported in 2.9% and 4.9% of the combination groups, versus 4.9% with placebo. Safety summary.
Reading efficacy and discontinuation together gives a more useful picture than a headline percentage alone. Full event tables and longer follow-up would be needed for a more detailed safety assessment than this selected-source article provides.
What is new, and what remains unresolved?
The November publication provides the trial report; it should not be counted as an independent new experiment each time the same results appear at a meeting. As of the November 14 sponsor update, CagriSema remained investigational and was not approved in the United States. FDA’s information page, rechecked November 19, states that cagrilintide is not a component of an FDA-approved drug and has not been found safe and effective for any condition. FDA information. Dated development status.
Is this evidence for CagriSema in menopause?
REDEFINE 9 and the menopause analyses are separate pieces of evidence. Our CagriSema and menopause article explains the exploratory analyses of REDEFINE 1.
Can these results rank CagriSema against retatrutide or EloraTZP?
No direct comparison with those agents was performed here. Read the incretin research comparison and the EloraTZP study guide with their different populations and designs attached.
References
On November 19, 2026, we rechecked the two indexed abstracts, registry record, selected sponsor results and FDA cagrilintide statement. The publication and registry report different enrollment counts, as explained above. Full journal papers, supplements and individual-level data were not independently reviewed in this update.
